Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated June 17, 2022, reporting results of its annual meeting of stockholders held on that date. The company had 39,440,399 shares outstanding as of the April 18, 2022 record date, with 33,869,184 shares represented in person or by proxy, equal to 85.87% of shares entitled to vote.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial operating metrics.
Material Changes Versus the Prior Comparable Period
The filing reports corporate governance actions only and does not provide comparable-period financial information or identify material operating changes.
Meeting Results, Outlook, and Risks
- Director elections: Steven L. Hoerter and Angie You, Ph.D. were elected as Class II directors, each to serve until the 2025 annual meeting or until a successor is elected and qualified, or earlier resignation or removal.
- Votes for Steven L. Hoerter: 30,420,083 for, 21,252 withheld, and 3,427,848 broker non-votes.
- Votes for Angie You, Ph.D.: 30,420,703 for, 20,632 withheld, and 3,427,848 broker non-votes.
- Independent auditor: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 33,863,053 votes for, 6,025 against, and 105 abstentions.
- The filing provides no new financial guidance, management outlook, contingencies, or unusual financial items.
Facts Investors Should Verify
- Confirm the continuing service of the two elected Class II directors through the 2025 annual meeting, subject to earlier changes.
- Review the company’s subsequent filings for any changes to the board, committee assignments, or auditor relationship.
- Consult the company’s periodic reports for financial performance, cash runway, liquidity, debt, clinical-program updates, and risk factors, none of which are addressed in this filing.